Page 5 - Management Theory 2023-2024 Edition
P. 5

www.pharmacyexam.com                                                                  Krisman

                                                 Table of Contents



            1. Social and Behavioral Aspect of  Pharmaceutical Care ..........................................................................................7

            2. Health Behavior ......................................................................................................................................................8

            3. Illness, Sickness and Disease ..................................................................................................................................9

            4. Prescribing Behavior of Healthcare Providers ..................................................................................................... 17

            5. Theories of Human Inference .............................................................................................................................. 19

            6. Barriers To Interprofessional Relations ............................................................................................................... 21

            7. Consumer Behavior Models ................................................................................................................................ 23
            8. Different Models of Patient-Practitioner Relationship ....................................................................................... 26

            9. A Model for Analyzing The Medication Use Process ........................................................................................... 28

            10. Noncompliance and Factors Affecting Noncompliance .................................................................................... 29

            11. Prescription Errors and Pharmacists’ Responsibility ......................................................................................... 31

            12. ECHO Model and Economic Outcomes ............................................................................................................. 38

            13. Differential Analysis ........................................................................................................................................... 49

            14. Instruments To Measure the Quality of Life ..................................................................................................... 52
            15. Pricing Strategy for New Products ..................................................................................................................... 55

            16. DRGs (Diagnosis Related Groups) ...................................................................................................................... 60

            17. Managed Care Organizations ............................................................................................................................ 63

            18. Pharmacy Benefit Management (PBM) ............................................................................................................. 71

            19. PBMs Performance Indicators ........................................................................................................................... 80

            20. Growth of Pharmacy Benefit Management (PBMs) .......................................................................................... 82

            21. Medicaid and Pharmacy Benefit Management (PBM) ...................................................................................... 83

            22. Medicare and Pharmacy Benefit Management (PBM) ..................................................................................... 87

            23. Professions With Drug Prescribing Authority .................................................................................................... 94
            24. Electronic Prescribing and Its Outcomes ........................................................................................................... 95

            25. Disease Management Programs ........................................................................................................................ 96

            26. Collaborative Practice Agreements ................................................................................................................... 98



                                                              4
   1   2   3   4   5   6   7   8   9   10